Aligos Therapeutics, Inc.
NASDAQ:ALGS
38.85 (USD) • At close December 23, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Aligos Therapeutics, Inc. |
Symbool | ALGS |
Munteenheid | USD |
Prijs | 38.85 |
Beurswaarde | 134,584,170 |
Dividendpercentage | 0% |
52-weken bereik | 6.76 - 42.947 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Lawrence M. Blatt MBA, Ph.D. |
Website | https://www.aligos.com |
An error occurred while fetching data.
Over Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)